Beth Ann Smith - 02 Jan 2025 Form 3 Insider Report for MACROGENICS INC (MGNX)

Role: VP, Controller & Treasurer
Signature: Beth Smith
Issuer symbol: MGNX
Transactions as of: 02 Jan 2025
Net transactions value: $0
Form type: 3
Filing time: 13 Jan 2025, 16:39:09 UTC
Next filing: 11 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MGNX	Common Stock						7,889	02 Jan 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MGNX	Employee Stock Option (right to buy)							02 Jan 2025	Common Stock	3,000	$31.43	Direct	F1
holding	MGNX	Employee Stock Option (right to buy)							02 Jan 2025	Common Stock	2,100	$20.53	Direct	F2
holding	MGNX	Employee Stock Option (right to buy)							02 Jan 2025	Common Stock	4,000	$28.94	Direct	F3
holding	MGNX	Employee Stock Option (right to buy)							02 Jan 2025	Common Stock	19,850	$21.88	Direct	F4
holding	MGNX	Employee Stock Option (right to buy)							02 Jan 2025	Common Stock	4,500	$11.50	Direct	F5
holding	MGNX	Employee Stock Option (right to buy)							02 Jan 2025	Common Stock	5,000	$19.18	Direct	F6
holding	MGNX	Employee Stock Option (right to buy)							02 Jan 2025	Common Stock	6,000	$10.15	Direct	F7
holding	MGNX	Employee Stock Option (right to buy)							02 Jan 2025	Common Stock	8,000	$2.44	Direct	F8
holding	MGNX	Employee Stock Option (right to buy)							02 Jan 2025	Common Stock	15,000	$4.82	Direct	F9
holding	MGNX	Restricted Stock Unit							02 Jan 2025	Common Stock	2,190	$0.000000	Direct	F10, F11
holding	MGNX	Employee Stock Option (right to buy)							02 Jan 2025	Common Stock	12,250	$18.30	Direct	F12
holding	MGNX	Restricted Stock Unit							02 Jan 2025	Common Stock	4,750	$0.000000	Direct	F11, F13

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was granted on 12/18/2015 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F2	This option was granted on 2/15/2017 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F3	This option was granted on 3/2/2018 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F4	This option was granted on 2/21/2019 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F5	This option was granted on 2/20/2020 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F6	This option was granted on 2/22/2021 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F7	This option was granted on 2/22/2022 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F8	This option was granted on 6/13/2022 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F9	This option was granted on 2/15/2023 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F10	The restricted stock units (RSUs) were granted on 2/15/2023 and vested as to 50% of the total shares one year after the date of grant and will vest 50% two years after the date of grant.
F11	Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F12	This option was granted on 2/8/2024 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F13	The restricted stock units (RSUs) were granted on 2/8/2024 and will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.